Uprifosbuvir

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameUprifosbuvir

Drug Alias Name乌弗布韦Next-generation uridine nucleotide prodrug inhibitor (IDX21437) - Idenix Pharmaceuticals乌普立布韦Uridine nucleotide analog (IDX21437) - Idenix PharmaceuticalsUprifosbuvirum +[8]

ClassificationSmall molecules > Nucleosides and nucleotide derivtives

Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors

TargetsHepatitis C virus NS5B RNA-dependent RNA polymerase

Therapy Area/IndicationsHepatitisLiver DiseasesDigestive System Diseases +[9]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMerck & Co Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMerck Sharp & Dohme LLC

Active IndicationsN/A

Inactive IndicationsHepatitisLiver DiseasesDigestive System Diseases +[9]

Other Information

ATC CodeN/A